Prognostic role of body mass index (BMI) in patients with metastatic castration resistant prostate cancer (mCRPC) receiving chemotherapy: Preliminary results from a retrospective Italian multicenter study.

2016 ◽  
Vol 34 (2_suppl) ◽  
pp. 342-342
Author(s):  
Stefania Eufemia Lutrino ◽  
Caterina Fontanella ◽  
Orazio Caffo ◽  
Francesco Massari ◽  
Francesco Atzori ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Body Mass Index ◽  
Body Mass ◽  
Multicenter Study ◽  
Normal Weight ◽  
World Health ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
The Relationship ◽  
High Bmi

342 Background: Body mass index (BMI) is linked to an increased risk of cancers and a poorer prognosis. However, the evidence on the relationship between high BMI and metastatic castration resistant prostate cancer (mCRPC) is not entirely consistent and the data are conflicting. The aim of this observational, retrospective, multicenter study was to evaluate the correlation between BMI and progression-free survival (PFS) and overall survival (OS) in patients (pts) with mCRPC treated with chemotherapy. Methods: We collected mCRPC pts who received docetaxel 75 mg/m2 every 21 days as first line therapy in6 Italian Cancer Centers from 2005 to 2015. We classified BMI group according with the World Health Organization definition : normal weight BMI < 25kg/m2, overweight 25 ≤ BMI < 30kg/m2, and obese BMI ≥ 30kg/m2. Baseline characteristics and treatment information has been recorded in an anonymized excel file. Results: We collected 113 pts with a median age of 70.7 years (62 to 87) at the time of mCRPC diagnosis. In our cohort 33.6% of pts were normal weight at the HRPC diagnosis, 50.9% were overweight, and 15.5% were obese. At the baseline, 83.3% of obese pts had at least 1 co-morbidity versus 64.9% of normal/overweight pts. Moreover, 27.8% of obese pts needed a docetaxel dose reduction versus 17.5% normal/overweight pts. Only a non-significant trend for the detrimental effect of high BMI on PFS and OS has been documented. Median PFS in obese pts 6.4 months vs 7.0 months in of normal/overweight pts (p = 0.439); median OS in obese pts 38.8 months vs 43.4 months in of normal/overweight pts (p = 0.157). Conclusions: The relationship between BMI and mCRPC is extremely complex and unclear. Even if in this preliminary analysis we failed to confirm a significant association between BMI and survival, the data suggests that obesity may be associated with a lower tolerance to chemotherapy. Overall, we expected to enroll approximately 500 pts and data collection is currently ongoing.

scholarly journals Prognostic Value of Body Mass Index in Korean Patients with Castration-Resistant Prostate Cancer

2012 ◽  
Vol 53 (11) ◽  
pp. 761 ◽  
Author(s):  
Jeong Min Park ◽  
Jung Soo Nam ◽  
Woong Na ◽  
Jong Jin Oh ◽  
Sangchul Lee ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Body Mass Index ◽  
Body Mass ◽  
Prognostic Value ◽  
Castration Resistant Prostate Cancer ◽  
Korean Patients ◽  
Castration Resistant

PRO-BMI study: prognostic role of body mass index (BMI) in metastatic castration resistant prostate cancer (mCRPC) patients receiving chemotherapy.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. e16543-e16543
Author(s):  
Marcello Tucci ◽  
Stefania Eufemia Lutrino ◽  
Massimo Di Maio ◽  
Giuseppe Procopio ◽  
Francesco Massari ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Body Mass Index ◽  
Body Mass ◽  
Castration Resistant Prostate Cancer ◽  
Prognostic Role ◽  
Castration Resistant

scholarly journals Higher body mass index is associated with larger postoperative improvement in patient-reported outcomes following total knee arthroplasty

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
K Giesinger ◽  
JM Giesinger ◽  
DF Hamilton ◽  
J Rechsteiner ◽  
A Ladurner
Keyword(s):  
Body Mass Index ◽  
Total Knee Arthroplasty ◽  
Pain Relief ◽  
Body Mass ◽  
Knee Arthroplasty ◽  
Normal Weight ◽  
World Health ◽  
Obese Patients ◽  
Total Knee ◽  
The Impact

Abstract Background Total knee arthroplasty is known to successfully alleviate pain and improve function in endstage knee osteoarthritis. However, there is some controversy with regard to the influence of obesity on clinical benefits after TKA. The aim of this study was to investigate the impact of body mass index (BMI) on improvement in pain, function and general health status following total knee arthroplasty (TKA). Methods A single-centre retrospective analysis of primary TKAs performed between 2006 and 2016 was performed. Data were collected preoperatively and 12-month postoperatively using WOMAC score and EQ-5D. Longitudinal score change was compared across the BMI categories identified by the World Health Organization. Results Data from 1565 patients [mean age 69.1, 62.2% women] were accessed. Weight distribution was: 21.2% BMI < 25.0 kg/m2, 36.9% BMI 25.0–29.9 kg/m2, 27.0% BMI 30.0–34.9 kg/m2, 10.2% BMI 35.0–39.9 kg/m2, and 4.6% BMI ≥ 40.0 kg/m2. All outcome measures improved between preoperative and 12-month follow-up (p < 0.001). In pairwise comparisons against normal weight patients, patients with class I-II obesity showed larger improvement on the WOMAC function and total score. For WOMAC pain improvements were larger for all three obesity classes. Conclusions Post-operative improvement in joint-specific outcomes was larger in obese patients compared to normal weight patients. These findings suggest that obese patients may have the greatest benefits from TKA with regard to function and pain relief one year post-op. Well balanced treatment decisions should fully account for both: Higher benefits in terms of pain relief and function as well as increased potential risks and complications. Trial registration This trial has been registered with the ethics committee of Eastern Switzerland (EKOS; Project-ID: EKOS 2020–00,879)

scholarly journals Analisis Antimullerian Hormon (AMH) di Dalam Serum pada Berbagai Kategori Indeks Masa Tubuh

2019 ◽  
Vol 5 (1) ◽  
pp. 162-168
Author(s):  
Didik Rio Pambudi ◽  
Ashon Sa�adi ◽  
Sudjarwo Sudjarwo
Keyword(s):  
Body Mass Index ◽  
Body Mass ◽  
Normal Weight ◽  
Uterine Bleeding ◽  
Obese Women ◽  
Height Measurement ◽  
Normality Test ◽  
Laboratory Infection ◽  
Special Hospital ◽  
The Relationship

Obesity-related to the result of decreased reproduction. Obese women are more prone to abnormal anovulation and uterine bleeding, endometrial hyperplasia/cancer, infertility, miscarriage, and pregnancy complications, compared to women of normal weight. This study aims to determine the levels of anti-Mullerian hormone (AMH) in the serum at various BMI (body mass index), also to determine the relationship and correlation between obesity and AMH levels in serum. The population in the study were women aged 20 years to 40 years with less BMI, Normal BMI and Obesity BMI. The study subjects were women between the ages of 20 to 40 years with a BMI less than 17-19.9, obesity BMI = 25 and normal BMI 20-25 as controls. Height measurement, weight weighing, and BMI calculation carried out according to the standard and subject to approval. Taking blood samples for the examination of AMH levels carried out by the RSKI laboratory (Infection Special Hospital) Airlangga University. The results of the data processed with SPSS 25 with the Shapiro-Wilk normality test and Mann Whitney statistical analysis for different tests and Spearman analysis for the correlation test. The results of the study found homogeneous samples, there were no significant differences between the AMH levels of the less and obese groups with, p = 0.832 (p> 0.05). AMH levels in BMI were less (0.459 � 0.112 ng / mL) than obesity BMI (0.432 � 0.058 ng / mL), so it was concluded that AMH levels did not correlate with less BMI with obesity BMI, with a correlation value (r) = -0.105 (p = 0.643; p> 0.05). The results of this study concluded that body mass index not related and does not correlate with the levels of anti-Mullerian hormone in the serum.

scholarly journals Clinical Verification of Body Mass Index and Tumor Immune Response in Patients With Breast Cancer Receiving Preoperative Chemotherapy

2021 ◽  
Author(s):  
Koji Takada ◽  
Shinichiro Kashiwagi ◽  
Yuka Asano ◽  
Wataru Goto ◽  
Rika Kouhashi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Body Mass Index ◽  
Body Mass ◽  
Preoperative Chemotherapy ◽  
Early Stage ◽  
Normal Weight ◽  
World Health ◽  
Cancer Type ◽  
Immune Microenvironment ◽  
Tumor Immune Microenvironment

Abstract PurposeThe body mass index (BMI) is commonly used as a simple indicator of obesity; patients with early-stage breast cancer who are obese (OB) per BMI measurements have been shown to have high postoperative recurrence and low survival rates. On the other hand, it has been shown that lymphocytes present in the vicinity of malignant growths that are involved in the tumors’ immune responses influence the efficacy chemotherapy. Therefore, we hypothesized that OB patients with breast cancer have a lower density of tumor-infiltrating lymphocytes (TILs), which may influence the therapeutic effect of preoperative chemotherapy (POC). In this study, we measured pretreatment BMI and TILs in patients with breast cancer who underwent POC, examined the correlations between these two factors, and retrospectively analyzed their therapeutic outcomes and prognoses.MethodsThe participants in this study were 421 patients with breast cancer who underwent surgical treatment after POC between February 2007 and January 2019. The patient’s height and weight were measured before POC to calculate the BMI (weight [kg] divided by the square of the height [m2]). According to the World Health Organization categorization, patients who weighed under 18.5 kg/m2 were classified as underweight (UW), those ≥18.5 kg/m2 and >25 kg/m2 were considered normal weight (NW), those ≥25 kg/m2 and <30 kg/m2 were overweight (OW), and those ≥30 kg/m2 were OB. The TILs were those lymphocytes that infiltrated the tumor stroma according to the definition of the International TILs Working Group 2014.ResultsThe median BMI was 21.9 kg/m2 (range, 14.3–38.5 kg/m2); most patients (244; 64.5%) were NW. Among all 378 patients with breast cancer, the TIL density was significantly lower in OB than in NW and OW patients (vs. NW: p=0.001; vs. OW: p=0.003). Furthermore, when examining patients with each breast cancer type individually, the OS of those with TNBC who had low BMIs was significantly poorer than that of their high-BMI counterparts (log rank p=0.031).ConclusionsOur data did not support the hypothesis that obesity affects the tumor immune microenvironment; however, we showed that being UW does affect the tumor immune microenvironment.

Sign in / Sign up

Export Citation Format

Share Document